1
TITLE: Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials  Full Text
AUTHORS: Kimball, Alexa B.; Jemec, Gregor B. E.; Alavi, Afsaneh; Reguiai, Ziad; Gottlieb, Alice B.; Bechara, Falk G.; Paul, Carle; Bourboulis, Evangelos J. Giamarellos; Villani, Axel P.; Schwinn, Andreas; Rueff, Franziska; Ramaya, Larisha Pillay; Reich, Adam; Lobo, Ines; Sinclair, Rodney; Passeron, Thierry; Martorell, Antonio; Mendes Bastos, Pedro; Kokolakis, Georgios; Becherel, Pierre Andre; Wozniak, Magdalena B.; Martinez, Angela Llobet; Wei, Xiaoling; Uhlmann, Lorenz; Passera, Anna; Keefe, Deborah; Martin, Ruvie; Field, Clarice; Chen, Li; Vandemeulebroecke, Marc; Ravichandran, Shoba; Muscianisi, Elisa; ...More
PUBLISHED: 2023, SOURCE: LANCET, VOLUME: 401, ISSUE: 10378
INDEXED IN: Scopus WOS
2
TITLE: Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region
AUTHORS: Alpalhao, Miguel; Duarte, Joana; Diogo, Rita; Vandemeulebroecke, Marc; Ortmann, Christine Elke; Kasparek, Torben; Filipe, Paulo;
PUBLISHED: 2022, SOURCE: BIODRUGS, VOLUME: 36, ISSUE: 6
INDEXED IN: WOS